|Preclinical Research||Clinical Research|
|Medicinal Discovery||Optimization of Drug Candidates||Preparations for Clinical Studies*||Clinical Phase I**||Clinical Phase II***||Phase III|
– Myocardial infarction (inflammation)
– Ovarian cancer
– First in human (cancer)
Since its foundation, Kancera has established world class preclinical research capabilities and demonstrated the ability to advance candidate drugs into clinical development. Kancera’s pipeline now consists of two candidate drugs that are being studied in three ongoing clinical trials:
FRACTAL – an ongoing phase IIa study of KAND567 in STEMI patients undergoing PCI
KANDOVA – an ongoing combined phase Ib/IIa study of KAND567 in ovarian cancer patients with relapse from carboplatin therapy
KAND145 First-in-human – a phase I study of Kancera’s second generation fractalkine blocker in healthy subjects
In addition to the clinical stage pipeline, Kancera is conducting preclinical research of its candidate drugs in potential new indications.
FRACTAL – KAND567 in myocardial infarction
FRACTAL is a phase IIa study in ST-elevated myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI). The study, a randomized, two-armed, placebo-controlled, double blinded, multi-center study, is conducted in collaboration with the NHS Foundation at two hospitals in the UK. Patient enrollment has been completed and 71 patients in total have been recruited. Top line results are expected to be presented in Q4 2023.
KANDOVA – KAND567 in ovarian cancer
KANDOVA is a combined phase Ib/IIa study in ovarian cancer patients with relapse from carboplatin therapy. The study is an open label, multi-center, dose escalation study with an expansion cohort of KAND567 in combination with carboplatin.
The study is conducted at several university hospitals in Sweden, Denmark and Norway. The first part (phase Ib) was initiated in Q2 2023 and the second part (phase IIa) is expected to start during Q2 2024.
KAND145 First-in-human – phase I study in healthy subjects
The study is a randomized, placebo-controller, multi-center, first in human study of KAND145 in healthy subjects to evaluate safety, tolerability, pharmacokinetics, food effect and drug interaction.
The study started in Q4 2023 and is conducted at two sites in Finland. Top line results are expected to be presented in Q2 2024.
Through its function as a regulator of certain immune cells, the fractalkine axis plays an important role in several acute and chronic inflammatory diseases, autoimmune disease as well as complications in connection with transplantations. Kancera is evaluating opportunities for treatment of new inflammatory diseases with high medical need of more effective treatments.
Kancera has presented preclinical results supporting the potential for KAND145 to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).